Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon

Zhang, Yuxuan; Zhang, Xinyi; Dong, Qichao; Chen, Delong; Xu, Yi; Jiang, Jun

doi:10.3389/fcvm.2021.762391

Cited by 12 publications

(9 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, current practice guidelines recommend aspirin and clopidogrel DAPT for patients suffering from CAD or monotherapy for patients with symptomatic PAD, regardless of clinical background [ 49 ]. However, there is controversy over the duration of antiplatelet therapy in view of the different lesion sites and stent types [ 50 ]. Cristian A Dámazo-Escobedo et al [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials

Sun,

Zhang,

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

Importance Diabetes mellitus (DM) is thought to be closely related to arterial stenotic or occlusive disease caused by atherosclerosis. However, there is still no definitive clinical evidence to confirm that patients with diabetes have a higher risk of restenosis. Objective This meta-analysis was conducted to determine the effect of DM on restenosis among patients undergoing endovascular treatment, such as percutaneous transluminal angioplasty (PTA) or stenting. Data sources and study selection The PubMed/Medline, EMBASE and Cochrane Library electronic databases were searched from 01/1990 to 12/2022, without language restrictions. Trials were included if they satisfied the following eligibility criteria: (1) RCTs of patients with or without DM; (2) lesions confined to the coronary arteries or femoral popliteal artery; (3) endovascular treatment via PTA or stenting; and (4) an outcome of restenosis at the target lesion site. The exclusion criteria included the following: (1) greater than 20% of patients lost to follow-up and (2) a secondary restenosis operation. Data extraction and synthesis Two researchers independently screened the titles and abstracts for relevance, obtained full texts of potentially eligible studies, and assessed suitability based on inclusion and exclusion criteria.. Disagreements were resolved through consultation with a third researcher. Treatment effects were measured by relative ratios (RRs) with 95% confidence intervals (CIs) using random effects models. The quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Main outcomes and measures The main observation endpoint was restenosis, including > 50% stenosis at angiography, or TLR of the primary operation lesion during the follow-up period. Results A total of 31,066 patients from 20 RCTs were included. Patients with DM had a higher risk of primary restenosis after endovascular treatment (RR = 1.43, 95% CI: 1.25–1.62; p = 0.001). Conclusions and relevance This meta-analysis of all currently available RCTs showed that patients with DM are more prone to primary restenosis after endovascular treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials

Sun,

Zhang,

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…Compared with DES, implantation without a foreign body seems to be an obvious advantage of DCB. There is no inflammation caused by the implantation of foreign body ( 89 ). Theoretically, the DAPT time after the implantation of DCB should be shorter than that of the DES group.…”

Section: The Influencing Factors On Drug-coated Balloon Efficiencymentioning

confidence: 99%

The factors influencing the efficiency of drug-coated balloons

Cao

Zhao

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The drug-coated balloon (DCB) is an emerging percutaneous coronary intervention (PCI) device that delivers drugs to diseased vessels to decrease the rate of vascular stenosis. Recent clinical studies have demonstrated that DCBs tend to have both good safety and efficacy profiles, leading to extended application indications in the clinic, including in-stent restenosis (ISR) for metal stents such as drug-eluting stents (DESs), small vascular disease, bifurcation disease, large vascular disease, acute coronary syndrome (ACS), and high bleeding risk. However, some previous clinical data have suggested that DCBs performed less effectively than DESs. No studies or reviews have systematically discussed the improvement strategies for better DCB performance until now. Drug loss during the process of delivery to the target lesion and inefficient delivery of the coating drug to the diseased vascular wall are two key mechanisms that weaken the efficiency of DCBs. This review is the first to summarize the key influencing factors of DCB efficiency in terms of balloon structure and principles, and then it analyzes how these factors cause outcomes in practice based on current clinical trial studies of DCBs in the treatment of different types of lesions. We also provide some recommendations for improving DCBs to contribute to better DCB performance by improving the design of DCBs and combining other factors in clinical practice.

show abstract

“…Drug-coated balloon (DCB) allows the release of anti-proliferative agents to the vascular wall through a semi-compliant balloon without leaving any metal, which can inhibit the proliferation of vascular smooth muscle cells ( 7 ). DCB has been reported to have good efficacy and safety for in-stent restenosis and new-onset small vessel disease ( 8 ). DCB could also be a promising treatment modality for SB ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of drug-coated balloon combined with cutting balloon for side branch of true coronary bifurcation lesions: Study protocol for a multicenter, prospective, randomized controlled trial

Deng²,

Liu³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundCoronary bifurcation lesions are common of percutaneous coronary intervention (PCI), and the optimal interventional therapy strategy is still a matter of debate and remains a challenge for interventional cardiologists. The provisional stenting technique is still a preferred method for most bifurcation lesions, but restenosis of the side branch (SB) occurs in approximately 17–19% of cases. Therefore, the dilemma of reducing SB restenosis still exists, and further research on strategies to reduce restenosis for SB is necessary. Drug-coated balloon (DCB) can reduce clinical events in small vessel disease and in-stent restenosis. The efficacy and safety of DCB for SB of true coronary bifurcation lesions have not been fully investigated. A randomized comparison of DCB combined with cutting balloon angioplasty vs. cutting balloon angioplasty for SB has never been published.Methods and designThe purpose of this study is to explore the superiority of DCB combined with cutting balloon vs. cutting balloon angioplasty for SB after main vessel (MV) drug-eluting stent implantation of true coronary bifurcation lesions. This study is a multicenter, prospective, randomized controlled trial including 140 patients with true coronary bifurcation lesions. Patients will be randomized in a 1:1 manner to receive either DCB combined with cutting balloon or cutting balloon angioplasty for SB after MV drug-eluting stent implantation. The primary endpoint is the evaluation of late lumen loss (LLL) of SB at the 9-month follow-up. The secondary endpoints include procedural success during initial hospitalization, LLL of MV at the 9-month follow-up, binary angiographic restenosis in MV and SB at the 9-month follow-up, the proportion of patients with a final post-PCI quantitative flow ratio result ≤ 0.80 for SB at the 9-month follow-up, and major adverse cardiac events during the 24-month follow-up.ConclusionsThis clinical trial will provide evidence as to whether DCB combined with cutting balloon for SB of true coronary bifurcation lesions is a superior treatment approach.Trial Registration NumberChiCTR2000040475.DisseminationThe results of this clinical trial will be published in a peer-reviewed journal.

show abstract

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon

Cited by 12 publications

References 77 publications

Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials

Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials

The factors influencing the efficiency of drug-coated balloons

Efficacy and safety of drug-coated balloon combined with cutting balloon for side branch of true coronary bifurcation lesions: Study protocol for a multicenter, prospective, randomized controlled trial

Contact Info

Product

Resources

About